Pentraxin 3: A promising therapeutic target for autoimmune diseases
- 10 June 2020
- journal article
- research article
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 19 (12), 102584
- https://doi.org/10.1016/j.autrev.2020.102584
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81872687, 81573222)
- SZ (AR059103)
- STaR award (R61 AR073409)
This publication has 126 references indexed in Scilit:
- Expression of recombinant human complement C1q allows identification of the C1r/C1s-binding sitesProceedings of the National Academy of Sciences of the United States of America, 2013
- Polyclonal CD4+Foxp3+ Treg cells induce TGFβ-dependent tolerogenic dendritic cells that suppress the murine lupus-like syndromeJournal of Molecular Cell Biology, 2012
- Cell Death in the Maintenance and Abrogation of Tolerance: The Five Ws of Dying CellsImmunity, 2011
- Heterocomplexes of Mannose-binding Lectin and the Pentraxins PTX3 or Serum Amyloid P Component Trigger Cross-activation of the Complement SystemOnline Journal of Public Health Informatics, 2011
- The Angiogenic Inhibitor Long Pentraxin PTX3 Forms an Asymmetric Octamer with Two Binding Sites for FGF2Online Journal of Public Health Informatics, 2010
- Matrix metalloproteinase-8 deficiency increases joint inflammation and bone erosion in the K/BxN serum-transfer arthritis modelArthritis Research & Therapy, 2010
- Pathogen Recognition and Inflammatory Signaling in Innate Immune DefensesClinical Microbiology Reviews, 2009
- Developments in the scientific and clinical understanding of the spondyloarthritidesArthritis Research & Therapy, 2009
- Multiple sclerosisThe Lancet, 2008
- The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular trapsThe Journal of Experimental Medicine, 2007